Pfizer Inc


  • Pfizer's CFO Resigns, R&D President to Retire Monday, 21 May 2007 | 9:55 AM ET
    Pfizer's CEO Jeff Kindler.

    Jeffrey Kindler, the chief executive of  drug maker Pfizer Inc., continued to clean house with the announcement late Sunday that the company's research and development chief and chief financial officer will soon leave.  John LaMattina, president of global research and development, will retire  by the end of the year.  Alan Levin, the CFO, also resigned.

  • Company-Changing CEOs Monday, 14 May 2007 | 8:19 PM ET

    This week Cramer is doing a series on CEOs, the best of the best when it comes to company turnarounds. These five executives have turned their once-dead franchises into living, thriving businesses. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks That Pay Dividends Are A Good Bet For Retirement Thursday, 10 May 2007 | 10:26 AM ET

    Joseph Keating, chief investment officer at First American Asset Management, told CNBC’s “Squawk on the Street” that dividend stocks are a good bet in retirement.

  • Sanofi-Aventis Reports Declining First-Quarter Profits Thursday, 3 May 2007 | 8:38 AM ET

    French drugmaker Sanofi-Aventis on Thursday reported declining first-quarter profits, citing adverse currency movements, generic competition and a strong quarter in 2006.

  • Bristol-Myers Squibb's  recent agreements with rival drug companies to develop and sell drugs is a signal that the company is committed to staying independent, reports CNBC's David Faber.

  • Pfizer Unit Pleads Guilty to Kickback Thursday, 26 Apr 2007 | 12:15 AM ET

    Pharmacia and Upjohn Company, a unit of Pfizer, pleaded guilty to one count of offering a kickback to a pharmacy benefit manager and was sentenced to pay a criminal fine of $19.68 million, federal prosecutors said on Wednesday.

  • The U.S. dollar inched lower Wednesday -- as the euro approached its historic high. What does the transatlantic currency gap mean for America's economy? "Upside surprises," for one thing. David Gilmore, partner at Foreign Exchange Analytics, and Robert Lynch, currency analyst at HSBC, joined "Morning Call" to explain why the ever-weaker dollar may boost parts of the U.S. economy.

  • Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.

  • Hot Stocks: MedImmune, Coal Stocks Among Big Movers Monday, 23 Apr 2007 | 5:33 PM ET

    M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.

  • Stocks closed lower as cautious comments from GM and Pfizer snapped the Dow's seven-day winning streak. "We've seen a really good move in the market and a little consolidation is healthy," said Bill Nichols, managing director of equity trading for Bear Stearns. "After being higher so much, a little profit-taking is only natural."

  • Pfizer said quarterly earnings fell 18%, hurt by one-time charges and anemic sales of inhaled diabetes drug Exubera, plunging demand for drugs facing generic competition. The world's largest drugmaker also warned its 2007 earnings will be below Wall Street expectations due to the unexpectedly swift introduction of cheaper generic forms of its hypertension treatment Norvasc.

  • Rethinking CEO Pay Wednesday, 18 Apr 2007 | 11:34 AM ET

    What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects.

  • A Sense about Stents Tuesday, 17 Apr 2007 | 2:55 PM ET

    Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs  have come under increasing scrutiny over safety.

  • Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.

  • A Whole New Animal Hospital Friday, 13 Apr 2007 | 6:24 PM ET

    Health care and insurance are two of the fastest-growing segments of the booming pet market. And big drug makers such as Pfizer, Novartis and Eli Lilly have taken note.

  • No. 1 - Big Pharma Buyout Boom Friday, 13 Apr 2007 | 10:54 AM ET

    The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.

  • Merck shares rose sharply Friday after the drugmaker raised its outlook for first-quarter and full-year earnings, citing strong sales across its range of products, and said a federal court judge dismissed a class-action securities lawsuit against the company.

  • Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. A Food and Drug Administration drug safety expert earlier told the panel that the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.

  • Daughter of Vioxx Tuesday, 10 Apr 2007 | 4:31 PM ET

    Since another pharmaceutical industry blog has already posted an item about this under the title, "Son of Vioxx...." and since I don't want to be accused of plagiarism or sexism I've opted for "Daughter of Vioxx".

  • Mylan Shares Rise on Improved Earnings Guidance Tuesday, 10 Apr 2007 | 10:15 AM ET

    Mylan Laboratories raised its fiscal 2007 earnings forecast, citing the strong performance of its generic drugs business, pushing its shares up as much as 4%.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:25 PM ET

CNBC's Steve Liesman provides insight into the highlights of Fed Chair Janet Yellen's comments at The Economic Club of New York.

Wednesday, 16 Apr 2014 | 12:15 PM ET

Josh Spencer, T. Rowe Price portfolio manager, encourages investors to get some guts and buy into growth stocks like Tesla and Amazon. He shares his opinions on some of the old tech names.

Wednesday, 16 Apr 2014 | 10:01 AM ET

Discussing how to buy in volatile market conditions and the investment banking market, David Katz, Matrix Asset Advisors CIO, and Charles Bobrinskoy, Ariel Investments vice chairman & portfolio manager.